NASDAQ:CAPR Capricor Therapeutics (CAPR) Stock Price, News & Analysis $7.68 -0.58 (-7.02%) Closing price 04:00 PM EasternExtended Trading$7.78 +0.10 (+1.24%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Capricor Therapeutics Stock (NASDAQ:CAPR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Capricor Therapeutics alerts:Sign Up Key Stats Today's Range$6.93▼$8.0250-Day Range$6.35▼$14.2352-Week Range$3.52▼$23.40Volume5.48 million shsAverage Volume1.92 million shsMarket Capitalization$350.82 millionP/E RatioN/ADividend YieldN/APrice Target$36.67Consensus RatingBuy Company OverviewCapricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders. Read More… Capricor Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks48th Percentile Overall ScoreCAPR MarketRank™: Capricor Therapeutics scored higher than 48% of companies evaluated by MarketBeat, and ranked 523rd out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingCapricor Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCapricor Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Capricor Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Capricor Therapeutics are expected to grow in the coming year, from ($1.21) to ($0.75) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Capricor Therapeutics is -5.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Capricor Therapeutics is -5.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCapricor Therapeutics has a P/B Ratio of 2.40. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Capricor Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted27.69% of the float of Capricor Therapeutics has been sold short.Short Interest Ratio / Days to CoverCapricor Therapeutics has a short interest ratio ("days to cover") of 5.3.Change versus previous monthShort interest in Capricor Therapeutics has recently decreased by 19.59%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCapricor Therapeutics does not currently pay a dividend.Dividend GrowthCapricor Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted27.69% of the float of Capricor Therapeutics has been sold short.Short Interest Ratio / Days to CoverCapricor Therapeutics has a short interest ratio ("days to cover") of 5.3.Change versus previous monthShort interest in Capricor Therapeutics has recently decreased by 19.59%, indicating that investor sentiment is improving significantly. News and Social Media2.3 / 5News Sentiment0.14 News SentimentCapricor Therapeutics has a news sentiment score of 0.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.65 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 23 news articles for Capricor Therapeutics this week, compared to 6 articles on an average week.Search InterestOnly 1 people have searched for CAPR on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat Follows8 people have added Capricor Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Capricor Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders10.50% of the stock of Capricor Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 21.68% of the stock of Capricor Therapeutics is held by institutions.Read more about Capricor Therapeutics' insider trading history. Receive CAPR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Capricor Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CAPR Stock News HeadlinesWhy Is Capricor Therapeutics Stock Trading Lower On Monday?June 23 at 12:46 PM | benzinga.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPRJune 22 at 10:00 AM | prnewswire.comTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans a chance at true financial independence in the months ahead.” We recently sat down with Rickards to capture all the key details on tape. June 23, 2025 | Paradigm Press (Ad)Capricor Therapeutics announces four-year data from HOPE-2 OLE studyJune 21 at 3:08 PM | finance.yahoo.comCapricor Therapeutics stock plunges after key FDA officials placed on leaveJune 20 at 4:59 PM | in.investing.comCapricor falls after report on AdCom meeting cancellation (update)June 20 at 4:59 PM | msn.comCapricor Stock Slumps 16% On Report Of Key FDA Executive’s Removal, But Retail’s Hopeful About New 4-Year Deramiocel DataJune 20 at 4:59 PM | msn.comCapricor Reports 4-Year Data For Deramiocel, Shows Sustained Benefit In Duchenne PatientsJune 20 at 3:11 PM | benzinga.comSee More Headlines CAPR Stock Analysis - Frequently Asked Questions How have CAPR shares performed this year? Capricor Therapeutics' stock was trading at $13.80 at the beginning of the year. Since then, CAPR stock has decreased by 44.3% and is now trading at $7.68. View the best growth stocks for 2025 here. How were Capricor Therapeutics' earnings last quarter? Capricor Therapeutics, Inc. (NASDAQ:CAPR) released its earnings results on Tuesday, May, 13th. The biotechnology company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by $0.20. The biotechnology company had revenue of $2.73 million for the quarter, compared to the consensus estimate of $3.16 million. Capricor Therapeutics had a negative trailing twelve-month return on equity of 62.42% and a negative net margin of 181.71%. Read the conference call transcript. Who are Capricor Therapeutics' major shareholders? Top institutional shareholders of Capricor Therapeutics include Vanguard Group Inc. (4.96%), Woodline Partners LP (1.60%), Octagon Capital Advisors LP (0.99%) and Goldman Sachs Group Inc. (0.90%). Insiders that own company stock include Shinyaku Co Ltd Nippon, David B Musket, Paul Gisbert Auwaerter and Xavier Avat. View institutional ownership trends. How do I buy shares of Capricor Therapeutics? Shares of CAPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Capricor Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Capricor Therapeutics investors own include Advanced Micro Devices (AMD), Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Moderna (MRNA), Netflix (NFLX) and Alphabet (GOOG). Company Calendar Last Earnings5/13/2025Today6/23/2025Next Earnings (Estimated)8/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED PRODUCTS Sub-IndustryN/A Current SymbolNASDAQ:CAPR CIK1133869 Webwww.capricor.com Phone310-358-3200Fax415-875-7075EmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Target$36.67 High Stock Price Target$77.00 Low Stock Price Target$22.00 Potential Upside/Downside+377.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.42) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$40.47 million Net Margins-181.71% Pretax Margin-317.12% Return on Equity-62.42% Return on Assets-48.36% Debt Debt-to-Equity RatioN/A Current Ratio6.55 Quick Ratio6.55 Sales & Book Value Annual Sales$22.27 million Price / Sales15.75 Cash FlowN/A Price / Cash FlowN/A Book Value$3.20 per share Price / Book2.40Miscellaneous Outstanding Shares45,680,000Free Float40,881,000Market Cap$350.82 million OptionableOptionable Beta0.85 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (NASDAQ:CAPR) was last updated on 6/23/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Capricor Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Capricor Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.